Loading…

Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin

Uremic toxins are compounds normally excreted in urine that accumulate in patients with chronic kidney disease as a result of decreased renal clearance. Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin. The purpose of this study was to investigate in vitro the interact...

Full description

Saved in:
Bibliographic Details
Published in:Biochimie 2016-06, Vol.125, p.53-58
Main Authors: Saldanha, Juliana F., Yi, Dan, Stockler-Pinto, Milena B., Soula, Hédi A., Chambert, Stéphane, Fouque, Denis, Mafra, Denise, Soulage, Christophe O.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03
cites cdi_FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03
container_end_page 58
container_issue
container_start_page 53
container_title Biochimie
container_volume 125
creator Saldanha, Juliana F.
Yi, Dan
Stockler-Pinto, Milena B.
Soula, Hédi A.
Chambert, Stéphane
Fouque, Denis
Mafra, Denise
Soulage, Christophe O.
description Uremic toxins are compounds normally excreted in urine that accumulate in patients with chronic kidney disease as a result of decreased renal clearance. Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin. The purpose of this study was to investigate in vitro the interaction between PAA and human serum albumin (HSA) at physiological and pathological concentrations. We used ultrafiltration to show that there is a single high-affinity binding site for PAA on HSA, with a binding constant on the order of 3.4 × 104 M−1 and a maximal stoichiometry of 1.61 mol per mole. The PAA, at the concentration reported in end-stage renal patients, was 26% bound to albumin. Fluorescent probe competition experiments demonstrated that PAA did not bind to Sudlow's site I (in subdomain IIA) and only weakly bind to Sudlow's site II (in subdomain IIIA). The PAA showed no competition with other protein-bound uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to serum albumin. Our results provide evidence that human serum albumin can act as carrier protein for phenylacetic acid. •Phenylacetic acid (PAA) is an uremic toxins that accumulates in patients with chronic kidney disease.•Human serum albumin (HSA) is a protein carrier for PAA.•There is one single high-affinity binding site for PAA on HSA.•PAA does not compete with other hydrophobic uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to HSA.
doi_str_mv 10.1016/j.biochi.2016.03.002
format article
fullrecord <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_01601648v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S030090841630013X</els_id><sourcerecordid>1789047700</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03</originalsourceid><addsrcrecordid>eNp9UcFq3TAQFKGheUn7B6Xo2B7srCRbti6FkDZN4UEvuQtZWsd62PKrZIfm76uHkxwLgkWzs7PsDCGfGJQMmLw-lJ2f7eBLnn8liBKAn5Edk6ItJGvFO7IDAVAoaKsLcpnSAQBq4Oo9ueBSVXVb8R1x33HBOPlgFj8HOvd0GZB2PjgfHukxzkeMi8f02lkjTt7SZf7rAz0OGJ5HY3HJkLHeZZwO62QCTRjXiZqxW7P2B3LemzHhx5d6RR7ufjzc3hf73z9_3d7sCyuUXApeo0Bhbd856EE2vew7VLziVW0qrhg0nXS1MkYa5EYZ7GrlpIG-FlgbEFfk6yY7mFEfo59MfNaz8fr-Zq9PWDYqv6p9Ypn7ZePmE_-smBY9-WRxHE3AeU2aNa2CqmngJFttVBvnlCL2b9oM9CkKfdBbFPoUhQahcxR57PPLhrWb0L0NvXqfCd82AmZLnjxGnazHYNH5iHbRbvb_3_AP84yc4w</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1789047700</pqid></control><display><type>article</type><title>Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Saldanha, Juliana F. ; Yi, Dan ; Stockler-Pinto, Milena B. ; Soula, Hédi A. ; Chambert, Stéphane ; Fouque, Denis ; Mafra, Denise ; Soulage, Christophe O.</creator><creatorcontrib>Saldanha, Juliana F. ; Yi, Dan ; Stockler-Pinto, Milena B. ; Soula, Hédi A. ; Chambert, Stéphane ; Fouque, Denis ; Mafra, Denise ; Soulage, Christophe O.</creatorcontrib><description>Uremic toxins are compounds normally excreted in urine that accumulate in patients with chronic kidney disease as a result of decreased renal clearance. Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin. The purpose of this study was to investigate in vitro the interaction between PAA and human serum albumin (HSA) at physiological and pathological concentrations. We used ultrafiltration to show that there is a single high-affinity binding site for PAA on HSA, with a binding constant on the order of 3.4 × 104 M−1 and a maximal stoichiometry of 1.61 mol per mole. The PAA, at the concentration reported in end-stage renal patients, was 26% bound to albumin. Fluorescent probe competition experiments demonstrated that PAA did not bind to Sudlow's site I (in subdomain IIA) and only weakly bind to Sudlow's site II (in subdomain IIIA). The PAA showed no competition with other protein-bound uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to serum albumin. Our results provide evidence that human serum albumin can act as carrier protein for phenylacetic acid. •Phenylacetic acid (PAA) is an uremic toxins that accumulates in patients with chronic kidney disease.•Human serum albumin (HSA) is a protein carrier for PAA.•There is one single high-affinity binding site for PAA on HSA.•PAA does not compete with other hydrophobic uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to HSA.</description><identifier>ISSN: 0300-9084</identifier><identifier>EISSN: 1638-6183</identifier><identifier>DOI: 10.1016/j.biochi.2016.03.002</identifier><identifier>PMID: 26945842</identifier><language>eng</language><publisher>France: Elsevier B.V</publisher><subject>Cell Line ; Chronic kidney disease ; Human serum albumin ; Humans ; Life Sciences ; Phenylacetates - chemistry ; Phenylacetic acid ; Protein Binding ; Protein Domains ; Renal Insufficiency, Chronic - blood ; Serum Albumin - chemistry ; Serum Albumin - metabolism ; Uremic syndrome ; Uremic toxin</subject><ispartof>Biochimie, 2016-06, Vol.125, p.53-58</ispartof><rights>2016 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM)</rights><rights>Copyright © 2016 Elsevier B.V. and Société Française de Biochimie et Biologie Moléculaire (SFBBM). All rights reserved.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03</citedby><cites>FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03</cites><orcidid>0000-0001-6752-6056 ; 0000-0002-9707-7199 ; 0000-0001-5306-9712</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26945842$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-01601648$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Saldanha, Juliana F.</creatorcontrib><creatorcontrib>Yi, Dan</creatorcontrib><creatorcontrib>Stockler-Pinto, Milena B.</creatorcontrib><creatorcontrib>Soula, Hédi A.</creatorcontrib><creatorcontrib>Chambert, Stéphane</creatorcontrib><creatorcontrib>Fouque, Denis</creatorcontrib><creatorcontrib>Mafra, Denise</creatorcontrib><creatorcontrib>Soulage, Christophe O.</creatorcontrib><title>Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin</title><title>Biochimie</title><addtitle>Biochimie</addtitle><description>Uremic toxins are compounds normally excreted in urine that accumulate in patients with chronic kidney disease as a result of decreased renal clearance. Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin. The purpose of this study was to investigate in vitro the interaction between PAA and human serum albumin (HSA) at physiological and pathological concentrations. We used ultrafiltration to show that there is a single high-affinity binding site for PAA on HSA, with a binding constant on the order of 3.4 × 104 M−1 and a maximal stoichiometry of 1.61 mol per mole. The PAA, at the concentration reported in end-stage renal patients, was 26% bound to albumin. Fluorescent probe competition experiments demonstrated that PAA did not bind to Sudlow's site I (in subdomain IIA) and only weakly bind to Sudlow's site II (in subdomain IIIA). The PAA showed no competition with other protein-bound uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to serum albumin. Our results provide evidence that human serum albumin can act as carrier protein for phenylacetic acid. •Phenylacetic acid (PAA) is an uremic toxins that accumulates in patients with chronic kidney disease.•Human serum albumin (HSA) is a protein carrier for PAA.•There is one single high-affinity binding site for PAA on HSA.•PAA does not compete with other hydrophobic uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to HSA.</description><subject>Cell Line</subject><subject>Chronic kidney disease</subject><subject>Human serum albumin</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Phenylacetates - chemistry</subject><subject>Phenylacetic acid</subject><subject>Protein Binding</subject><subject>Protein Domains</subject><subject>Renal Insufficiency, Chronic - blood</subject><subject>Serum Albumin - chemistry</subject><subject>Serum Albumin - metabolism</subject><subject>Uremic syndrome</subject><subject>Uremic toxin</subject><issn>0300-9084</issn><issn>1638-6183</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9UcFq3TAQFKGheUn7B6Xo2B7srCRbti6FkDZN4UEvuQtZWsd62PKrZIfm76uHkxwLgkWzs7PsDCGfGJQMmLw-lJ2f7eBLnn8liBKAn5Edk6ItJGvFO7IDAVAoaKsLcpnSAQBq4Oo9ueBSVXVb8R1x33HBOPlgFj8HOvd0GZB2PjgfHukxzkeMi8f02lkjTt7SZf7rAz0OGJ5HY3HJkLHeZZwO62QCTRjXiZqxW7P2B3LemzHhx5d6RR7ufjzc3hf73z9_3d7sCyuUXApeo0Bhbd856EE2vew7VLziVW0qrhg0nXS1MkYa5EYZ7GrlpIG-FlgbEFfk6yY7mFEfo59MfNaz8fr-Zq9PWDYqv6p9Ypn7ZePmE_-smBY9-WRxHE3AeU2aNa2CqmngJFttVBvnlCL2b9oM9CkKfdBbFPoUhQahcxR57PPLhrWb0L0NvXqfCd82AmZLnjxGnazHYNH5iHbRbvb_3_AP84yc4w</recordid><startdate>201606</startdate><enddate>201606</enddate><creator>Saldanha, Juliana F.</creator><creator>Yi, Dan</creator><creator>Stockler-Pinto, Milena B.</creator><creator>Soula, Hédi A.</creator><creator>Chambert, Stéphane</creator><creator>Fouque, Denis</creator><creator>Mafra, Denise</creator><creator>Soulage, Christophe O.</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0001-6752-6056</orcidid><orcidid>https://orcid.org/0000-0002-9707-7199</orcidid><orcidid>https://orcid.org/0000-0001-5306-9712</orcidid></search><sort><creationdate>201606</creationdate><title>Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin</title><author>Saldanha, Juliana F. ; Yi, Dan ; Stockler-Pinto, Milena B. ; Soula, Hédi A. ; Chambert, Stéphane ; Fouque, Denis ; Mafra, Denise ; Soulage, Christophe O.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Cell Line</topic><topic>Chronic kidney disease</topic><topic>Human serum albumin</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Phenylacetates - chemistry</topic><topic>Phenylacetic acid</topic><topic>Protein Binding</topic><topic>Protein Domains</topic><topic>Renal Insufficiency, Chronic - blood</topic><topic>Serum Albumin - chemistry</topic><topic>Serum Albumin - metabolism</topic><topic>Uremic syndrome</topic><topic>Uremic toxin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Saldanha, Juliana F.</creatorcontrib><creatorcontrib>Yi, Dan</creatorcontrib><creatorcontrib>Stockler-Pinto, Milena B.</creatorcontrib><creatorcontrib>Soula, Hédi A.</creatorcontrib><creatorcontrib>Chambert, Stéphane</creatorcontrib><creatorcontrib>Fouque, Denis</creatorcontrib><creatorcontrib>Mafra, Denise</creatorcontrib><creatorcontrib>Soulage, Christophe O.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Biochimie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Saldanha, Juliana F.</au><au>Yi, Dan</au><au>Stockler-Pinto, Milena B.</au><au>Soula, Hédi A.</au><au>Chambert, Stéphane</au><au>Fouque, Denis</au><au>Mafra, Denise</au><au>Soulage, Christophe O.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin</atitle><jtitle>Biochimie</jtitle><addtitle>Biochimie</addtitle><date>2016-06</date><risdate>2016</risdate><volume>125</volume><spage>53</spage><epage>58</epage><pages>53-58</pages><issn>0300-9084</issn><eissn>1638-6183</eissn><abstract>Uremic toxins are compounds normally excreted in urine that accumulate in patients with chronic kidney disease as a result of decreased renal clearance. Phenylacetic acid (PAA) has been identified as a new protein bound uremic toxin. The purpose of this study was to investigate in vitro the interaction between PAA and human serum albumin (HSA) at physiological and pathological concentrations. We used ultrafiltration to show that there is a single high-affinity binding site for PAA on HSA, with a binding constant on the order of 3.4 × 104 M−1 and a maximal stoichiometry of 1.61 mol per mole. The PAA, at the concentration reported in end-stage renal patients, was 26% bound to albumin. Fluorescent probe competition experiments demonstrated that PAA did not bind to Sudlow's site I (in subdomain IIA) and only weakly bind to Sudlow's site II (in subdomain IIIA). The PAA showed no competition with other protein-bound uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to serum albumin. Our results provide evidence that human serum albumin can act as carrier protein for phenylacetic acid. •Phenylacetic acid (PAA) is an uremic toxins that accumulates in patients with chronic kidney disease.•Human serum albumin (HSA) is a protein carrier for PAA.•There is one single high-affinity binding site for PAA on HSA.•PAA does not compete with other hydrophobic uremic toxins such as p-cresyl-sulfate or indoxyl sulfate for binding to HSA.</abstract><cop>France</cop><pub>Elsevier B.V</pub><pmid>26945842</pmid><doi>10.1016/j.biochi.2016.03.002</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0001-6752-6056</orcidid><orcidid>https://orcid.org/0000-0002-9707-7199</orcidid><orcidid>https://orcid.org/0000-0001-5306-9712</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0300-9084
ispartof Biochimie, 2016-06, Vol.125, p.53-58
issn 0300-9084
1638-6183
language eng
recordid cdi_hal_primary_oai_HAL_hal_01601648v1
source ScienceDirect Freedom Collection 2022-2024
subjects Cell Line
Chronic kidney disease
Human serum albumin
Humans
Life Sciences
Phenylacetates - chemistry
Phenylacetic acid
Protein Binding
Protein Domains
Renal Insufficiency, Chronic - blood
Serum Albumin - chemistry
Serum Albumin - metabolism
Uremic syndrome
Uremic toxin
title Determination of the binding properties of the uremic toxin phenylacetic acid to human serum albumin
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A17%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Determination%20of%20the%20binding%20properties%20of%20the%20uremic%20toxin%20phenylacetic%20acid%20to%20human%20serum%20albumin&rft.jtitle=Biochimie&rft.au=Saldanha,%20Juliana%20F.&rft.date=2016-06&rft.volume=125&rft.spage=53&rft.epage=58&rft.pages=53-58&rft.issn=0300-9084&rft.eissn=1638-6183&rft_id=info:doi/10.1016/j.biochi.2016.03.002&rft_dat=%3Cproquest_hal_p%3E1789047700%3C/proquest_hal_p%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c396t-25e3e3ccfbd0f067f6fbe924245a429107b6d59aa6ae2a9aeb59d6a0f53e5a03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1789047700&rft_id=info:pmid/26945842&rfr_iscdi=true